Ocata Therapeutics Inc fka OCAT

[ddls]

ACTC is a money trap. You can see that there is no interest in stay-
ing in it from the way it's trading.
Now, it can't get above 9 cents.
The SEC is coming up next, so buyers beware!

Quote from ACT's 10Q-3
"We expect that research and development expenses will increase."
"We have no therapeutic products currently available for sale."
"We continue to repay our debt financing's in shares of common stock."

The 10Q-4 will be interesting to see how much sugar coating they do.
I wonder if it will include:
"We expect that research and development expenses will increase."
"We have no therapeutic products currently available for sale."
"We continue to repay our debt financing's in shares of common stock."